Clusterin as a Diagnostic and Prognostic Marker for Transitional Cell Carcinoma of the Bladder

Irani J, Heidenreich A, Mottet N et al (2008) What is new in bladder cancer diagnosis and management? Eur Urol supplements 7:484–493 Haitel A, Posch B, El-Baz M et al (2001) Bilharzial related organ confined muscle-invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, e-cadherin, epidermal growth factor receptor and c-erbB-2. J Urol 165:1481–1487 Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J et al (2000) Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol. 164:680–684 Cajulis RS, Haines GK 3rd, Frias-Hidvegi D et al (1995) Cytology, flow cytometry, image analysis, and interphase cytogenetics by fluorescence in situ hybridization in the diagnosis of transitional cell carcinoma in bladder washes: a comparative study. Diagn. Cytopathol. 13(3):214–224 Schmitz-Dräger BJ, Fradet Y, Grossman HB (2008) Bladder cancer markers in patient management: the current perspective. World J Urol 26:1–3 Blaschuk O, Burdzy K, Fritz IB (1983) Purification and characterization of a cell-aggregating factor (clusterin), the major glycoprotein in ram rete testis fluid. J Biol Chem. 258:7714–7720 Jenne DE, Tschopp J (1992) Clusterin: the intriguing guises of a widely expressed glycoprotein. Trends Biochem Sci. 17:154–159 Jones SE, Jomary C (2002) Clusterin. Int J Biochem Cell Biol. 34:427–431 Shannan B, Seifert M, Leskov K et al (2006) Challenge and promise: roles for clusterin in pathogenesis, progression and therapy of cancer. Cell Death and Differentiation J. 13:12–19 Parczyk K, Pilarsky C, Rachel U et al (1994) Gp80 (Clusterin: TRPM-2) mRNA levels is enhanced in human renal clear cell carcinomas. J Cancer Res Clin Oncol 120:186–188 Steinberg J, Oyasu R, Lang S et al (1997) Intracellular levels of SGP-2 (Clusterin) correlate with tumor grade in prostate cancer. Clin Cancer Res 3:1707–1711 Redondo M, Villar E, Torres-Muñoz J et al (2000) Overexpression of Clusterin in human breast carcinoma. Am J Pathol 157:393–399 Miyake H, Gleave M, Kamidono S et al (2002) Overexpression of clusterin in transitional cell carcinoma of the bladder is related to disease progression and recurrence. Urology 50:150–154 Krüger S, Mahnken A, Kausch I et al (2006) Value of clusterin immunoreactivity as a predictive factor in muscle-invasive urothelial bladder carcinoma. Urology 67(1):105–109 Epstein JI, Amin MB, Reuter VR et al (1998) The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Am J Surg Pathol 22:1435–1448 Park J, Park J, Ju S et al (2003) Clusterin mRNA expression in apoptotic and activated rat thymocytes. Cell Research 13(1):49–58 Petrie A, Sabin C (2005) Medical Statistics at a Glance. 2nd ed.,Blackwell Publishing Trougakso IP, So A, Jansen B et al (2004) Silencing expression of the clusterin/apolipoprotein J gene in human cancer cells using small interfering RNA induces spontaneous apoptosis, reduced growth ability, and cell sensitization to genotoxic and oxidative stress. Cancer Res. 64:1834–1842 Gleave M, Miyake H (2005) Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer. World J. Urol. 23:38–46 Wong P, Ulyanova T, Organisciak DT et al (2001) Expression of multiple forms of clusterin during light-induced retinal degeneration. Curr Eye Res 23:157–165 Leskov KS, Klokov DY, Li J et al (2003) Synthesis and functional analyses of nuclear clusterin, a cell death protein. J. Biol. Chem. 278:11590–11600 Pucci S, Bonanno E, Pichiorri F et al (2004) Modulation of different clusterin isoforms in human colon tumorigenesis. Oncogene 23:2298–2304 Chen X, Halberg RB, Ehrhardt WM et al (2003) Clusterin as a biomarker in murine and human intestinal neoplasia. Proc. Natl. Acad. Sci. USA 100:9530–9535 Saffer H, Wahed A, Rassidakis GZ et al (2002) Clusterin expression in malignant lymphomas. Mod. Pathol. 15:1221–1223 Stejskal D, Fiala RR (2006) Evaluation of serum and urine clusterin as a potential tumor marker for urinary bladder cancer. Neoplasma. 53(4):343–346 Miyake H, Hara I, Gleave ME et al (2004) Protection of androgen dependent human prostate cancer cells from oxidative stress-induced DNA damage by overexpression of clusterin and its modulation by androgen. Prostate 61:318–323 Zellweger T, Kiyama S, Chi K et al (2003) Overexpression of the cytoprotective protein clusterin decreases radiosensitivity in the human LNCaP prostate tumour model. BJU Int. 92:463–469 Scaltriti M, Brausi M, Amorosi A (2004) Clusterin (SGP-2, APOJ) expression is downregulated in low- and high-grade human prostate cancer. Int. J. Cancer 108:23–30 July LV, Beraldi E, So A et al (2004) Nucleotide-based therapies targeting clusterin chemosensitized human lung adenocarcinoma cells both in vitro and in vivo. Mol. Cancer Ther. 3:223–232 Zhang LY, Ying WT, Mao YS (2003) Loss of clusterin both in serum and tissue correlates with the tumorigenesis of oesophageal squamous cell carcinoma via proteomic approaches. World J Gastroenterol 9:650–654 Xie MJ, Motoo Y, Su SB et al (2002) Expression of clusterin in human pancreatic cancer. Pancreas 25:234–238 Miyake H, Hara I, Kamidono S et al (2001) Synergistic chemosensitization and inhibition of tumor growth and metastasis by the antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model. Clin Cancer Res 7:4245–4252 Miyake H, Nelson C, Rennie PS et al (2000) Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene, testosterone-repressed prostate message-2, in prostate cancer xenograft models. Cancer Res 60:2547–2554 Miyake H, Chi KN, Gleave ME (2000) Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgenindependent PC-3 prostate cancer cells both in vitro and in vivo. Clin Cancer Res 6:1655–1663 Miyake H, Hara I, Kamidono S et al (2001) Novel therapeutic strategy for advanced prostate cancer using antisense oligodeoxynucleotides targeting antiapoptotic genes up-regulated after androgen withdrawal to delay androgen-independent progression and enhance chemosensitivity. Int J Urol 8:337–349